Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | AGXT | P21549 | 2/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 4/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.39 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8338571 | 0.79 | TDP1 (0.77) | L3MBTL1TDP1ABCB1IDO1AGXT | |
| SCHEMBL27615709 | 0.79 | TDP1 (0.77) | L3MBTL1TDP1ABCB1IDO1AGXT | |
| SCHEMBL1268452 | 0.78 | L3MBTL1 (0.51) | L3MBTL1TDP1ABCB1IDO1AGXT | |
| SCHEMBL1268455 | 0.78 | L3MBTL1 (0.51) | L3MBTL1TDP1ABCB1IDO1AGXT | |
| SCHEMBL293291 | 0.77 | L3MBTL1 (0.57) | L3MBTL1TDP1ABCB1 | |
| SCHEMBL8499580 | 0.76 | IDO1 (0.61) | L3MBTL1TDP1IDO1AGXTLTA4H | |
| SCHEMBL8716189 | 0.75 | L3MBTL1 (0.70) | L3MBTL1TDP1ABCB1LTA4HCHRM3 | |
| SCHEMBL1838338 | 0.73 | TDP1 (0.54) | L3MBTL1TDP1IDO1AGXTLTA4H | |
| SCHEMBL19210361 | 0.73 | L3MBTL1 (0.88) | L3MBTL1TDP1ABCB1LTA4HCALM1 | |
| SCHEMBL4154354 | 0.73 | TDP1 (0.55) | L3MBTL1TDP1ABCB1IDO1AGXT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461385-B2 | Manufacture process of organic compounds | NOVARTIS AG (CH) | 2013-06-11 | — | — | US | disclosed |
| US-20090253811-A1 | MANUFACTURE PROCESS OF ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253811-A1 | MANUFACTURE PROCESS OF ORGANIC COMPOUNDS | NT5C, AADAC, DDC | L3MBTL1 4426/4885TDP1 4191/4885ABCB1 1684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.